Musi waNyamavhuvhu 24, 2022, US Food and Drug Administration (FDA) yakabvumira ibrutinib kuti irapwe vana vane makore anopfuura 1 vane chirwere chisingaperi chegraft-versus-host disease (cGVHD) vari kugamuchira Mushure mekukundikana kwe1- kana yakawanda-mutsara. systemic therapy .Chiratidzo chakatenderwa chakanyanya kuvarwere vevana, ine huwandu hwekupindura hwese hwe60% pavhiki makumi maviri neshanu, uye magadzirirwo emushonga anosanganisira capsules, mahwendefa uye nemuromo kumiswa.
Ibrutinib, BTK inhibitor yakagadziridzwa nePharmacyclics/Johnson & Johnson, inonzi kinase inhibitor yakambobvumidzwa kurapwa kwechisingaperi lymphocytic leukemia pamwe nesero lymphoma nezvimwe zvirwere.
Suntech inotarisa mukusimudzira uye kugadzirwa kwemishonga yepakati uye APIs uchishandisa green tekinoroji.Parizvino, kambani yedu yakagadzira zvigadzirwa zvitatu zvepakati zve ibrutinib zvinosanganisira C AS: 143900-44-1 , C AS: 330792-70-6 , C AS: 330786-24-8 , zvese zvakatengeswa mukugadzira mafekitori eGMP. .Pakati pavo, iyo yepakati yeC AS: 143900-44-1 inogadzirwa nemakemikari-enzymatic teknolojia , iyo ine zvakanakira zvegirinhi kuchengetedzwa kwezvakatipoteredza, mutengo wakaderera uye wepamusoro.Kugamuchirwa kubvunza uye kubatana!
Nguva yekutumira: Nov-04-2022